Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 10/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6005401 | 0.79 | LTA4H (0.50) | LTA4HSMN1; SMN2ALDH1A1MAPTSLC6A9 | |
| SCHEMBL6006261 | 0.79 | LTA4H (0.50) | LTA4HSMN1; SMN2ALDH1A1MAPTSLC6A9 | |
| SCHEMBL6003359 | 0.78 | LTA4H (0.49) | LTA4HSMN1; SMN2ALDH1A1MAPTSLC6A9 | |
| SCHEMBL6004132 | 0.75 | SLC6A9 (0.64) | ALDH1A1MAPTSLC6A9 | |
| SCHEMBL6005570 | 0.74 | LTA4H (0.46) | LTA4HSMN1; SMN2ALDH1A1MAPTSLC6A9 | |
| Fumaric Acid SCHEMBL6937135 | 0.72 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1MAPTNPSR1PKM | |
| Fumaric Acid SCHEMBL6937142 | 0.72 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1MAPTNPSR1PKM | |
| SCHEMBL13236794 | 0.72 | AHR (0.41) | SMN1; SMN2ALDH1A1HPGDHTTKDM4E | |
| SCHEMBL6006325 | 0.71 | SLC6A9 (0.72) | ALDH1A1MAPTSLC6A9 | |
| Hydrochloric Acid SCHEMBL6934707 | 0.71 | HTR2A (0.45) | SMN1; SMN2ALDH1A1MAPTNPSR1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287298-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | ALLELIX NEUROSCIENCE INC. | 2006-12-21 | — | — | US | disclosed |
| EP-1014966-B1 | PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | ALLELIX NEUROSCIENCE INC (US) | 2006-08-02 | — | — | EP | disclosed |
| US-7019024-B2 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | ALLELIX NEUROSCIENCE INC. (US) | 2006-03-28 | — | — | US | disclosed |
| US-20010012857-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | NPS PHARMACEUTICALS, INC. | 2001-08-09 | — | — | US | disclosed |
| US-6191165-B1 | ANTIDEPRESSANTS; SCHIZOPHRENIA; ALZHEIMER'S DISEASE; ANTIEPILEPTIC AGENTS | ALLELIX NEUROSCIENCE INC. | 2001-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287298-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | SLC18A2, SLC6A1, SLC6A11 | LTA4H 1840/4885SMN1; SMN2 117/4885ALDH1A1 806/4885 |
| US-20010012857-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | SLC6A1, SLC18A2, SLC6A11 | LTA4H 2230/4885SMN1; SMN2 55/4885ALDH1A1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.